PharmaVOICE - 
Nov./Dec. 2009
Purchase Issue

In Every Issue
Social Media
Arecent Manhattan Research report states that 88% of all physicians [...]
By

Robin Robinson

Talent Pool
Pharmaceutical POOL Stanley BARSHAY Dr. Richard BOWLES Richard CLARK Willie [...]
By
On the Calendar
November 16-17 Pharmaceutical Coverage & Reimbursement Conference Washington, D.C. Q1 [...]
By
Index
Julian Adams, Ph.D. President, Research and ­Development and Chief Scientific [...]
By
PharmaTrax
Service Consolidation Recommended for Clinical trial Offices Emerging centralized clinical [...]
By
E-Media
IMS Health’s Ask IMS is a cost-effective, Web-based service that [...]
By
What’s New
inVentiv Health’s recently launched risk evaluation and mitigation strategy (REMS) [...]
By
UpFront
In Memoriam Linda Ley Ciccarelli Linda Ciccarelli, VP and senior [...]
By
Letter from the Editor
2010 — Time to Move Forward The consensus is pretty [...]
By

Taren Grom, Editor

On The Cover

The Year Ahead
Looking back to the varying changes and pressures the industry has endured, and ahead to how the industry will need to reinvent itself to continue to prosper, companies are adapting to longer-term marketplace trends and evolving patient needs. The industry is facing pressure from the economic, regulatory, and R&D environments. The industry’s movement toward transformation [...]
By

Denise Myshko and Robin Robinson

Features

The Safety First Era
The classwide requirement for Risk Evaluation and Mitigation Strategies (REMS) for opioid products is likely to have a profound impact on the pharmaceutical industry and healthcare. While most REMS involve only a medication guide — which is likely to have little impact on the prescribing process — experts say the Food and Drug Administration’s classwide [...]
By
Online Media: Will it Kill the Mass Media Stars?
Jeff Baker is President and CEO, Noble Marketing Group, a provider of PhRMA-compliant creative marketing solutions for pharmaceutical, ­biotechnology, and healthcare providers. For more information, visit gonoblerx.com. “There will be more focus on education ­versus branding, and because of the guideline changes, there is a lack of tools to distribute the message and excite the [...]
By

Robin Robinson

The Salesforce of the Future
Our experts agree: the salesforce of the future will be more specialized, more technically advanced, and more clinically savvy; oh, and there will be fewer feet on the street, finally. If the past year is any indication, the salesforce of the future is going to experience an extreme makeover. For one, it will be much [...]
By

Robin Robinson

RNAI Technology
Coming of Age: RNAi Technology As advances in genetics ­continue to improve our understanding of ­disease, RNAi will have the opportunity to create entirely new classes of medicines. Researchers say RNA-based therapeutic technology will have a tremendous impact on pharmaceutical research in the next five to 10 years. RNAi (RNA interference) represents a breakthrough in [...]
By

Denise Myshko

The Innovation Challenge
There has been a great deal of discussion related to the challenges­ ­hampering innovation to create differentiated medicines. Never before have research and cutting-edge science been more important to ensure a steady flow of innovation. Much has been made of the industry’s decline in R&D productivity over the last few years. While the number of [...]
By

Denise Myshko

R&D Business Models
The Changing R&D Business Model Companies throughout the industry are experimenting with new models designed to tackle the pipeline productivity challenge. harmaceutical research and development is facing many pressures, from decreased productivity to the impact of the economy to changing technology to an increasingly global environment. Companies are looking for solutions, but industry experts say [...]
By

Denise Myshko

Emerging Markets Poised for Growth
Emerging markets are growing in size and in importance for drug developers. Countries outside the traditional markets of the United States, Europe, and Japan are revamping their regulatory and legal systems and reforming their healthcare systems, and they are expected to contribute more to the global pharmaceutical industry. The seven “pharmerging” markets that IMS Health [...]
By

Denise Myshko

Reform, Consolidation, and Good Citizenry
Reform, Consolidation, and Good Citizenry Our experts featured in this issue identify healthcare reform, mergers and acquisitions, and corporate reputation as three of the many market changers that will impact how the industry does business in the future. Healthcare Reform: What’s to Come? The year-long legislative endeavor to create a healthcare reform bill that all [...]
By

Robin Robinson

Supply Chain Strategies
Companies need to evaluate their business through their value streams rather than by individual processes or components. ccording to Bob Silvers, managing director, at SSA & Co., by applying the rigors of Lean Six Sigma to underperforming areas, pharmaceutical companies can completely transform their supply chain and operating performance and deliver substantial benefits to the [...]
By

Denise Myshko

The Executive Suite
Meeting challenges head-on David E. I. Pyott, CBE Chairman of the Board and CEO Allergan Inc. Allergan draws stability, strength, and value from its growth equation — a business model that balances diverse specialties with a focused approach and a leadership presence in markets around the globe. R&D is the center of the enterprise and [...]
By
The Crystal Ball
We asked our readers to identify the top trends and market shapers they expect to define the various industry sectors in the coming year. Some of their responses may already be on your radar, while others may provide a new and ­different perspective. There’s little doubt that 2010 will be another year punctuated by continued [...]
By

Taren Grom, Editor

Brave New Digital World
Pharma companies must be bold and confident in their deployment of electronic solutions or risk being left behind on the technological superhighway.
By
What’s Missing in eSolutions: Enabling the Redefinition of Clinical Development
Waife & Associates Inc.
By
Next-Generation Bar Coding Can Revolutionize Health Care Promotion
Topin & Associates
By
Four Tips for Better Physician Recruitment
Qi, part of CommonHealth
By
Creating a Better Electronic Compliance Program
Qi, part of CommonHealth
By
eClinical Feedback: Why Sponsors Need an Integrated, Closed-Loop Clinical Process
Medidata Solutions
By
Mobile Marketing for Pharma: An Innovation Lab* Whitepaper
Compass Healthcare Communications
By
Just-in-Time Information Finally Arrives
AmerisourceBergen Specialty Group
By
FEEDBACK